Clinically relevant biomarkers in targeted radiotherapy

Clinical and Experimental Metastasis

Volumn 29, Issue 7, 2012, Pages 853-860

  Stea, Baldassarre ^a   Gordon, John ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

EGFR pathway inhibition; Hypoxia; Intrinsic radiosensitivity; Repopulation

Indexed keywords

DOUBLE STRANDED DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; HEMOGLOBIN; HISTONE H2AX; HISTONE H2AX GAMMA; HYDROXYL RADICAL; OXYGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SINGLE STRANDED DNA; TUMOR MARKER; UNCLASSIFIED DRUG;

APOPTOSIS; BRAIN RADIATION; CANCER CONTROL; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL HYPOXIA; CHROMOSOME ABERRATION; CLONOGENESIS; CONFERENCE PAPER; DOUBLE STRANDED DNA BREAK; GENE MUTATION; GENE OVEREXPRESSION; GENETIC SCREENING; GENOME; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERBARIC OXYGEN; IONIZING RADIATION; LUNG CANCER; MOLECULAR BIOLOGY; MUTATION; OXYGEN TENSION; OXYGENATION; PATIENT POSITIONING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSPECTIVE STUDY; PROTEIN EXPRESSION; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; RADIOSENSITIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; SINGLE STRANDED DNA BREAK; SQUAMOUS CELL CARCINOMA; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

CELL HYPOXIA; CELL PROLIFERATION; HUMANS; NEOPLASMS; RADIATION TOLERANCE; RADIOSURGERY; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84868212583     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-012-9523-z     Document Type: Conference Paper

References (29)

1. Williams FH (1901) The Roentgen rays in medicine and surgery as an aid in diagnosis and as a therapeutic agent. The McMillan Company, London
2. Hall E, Giaccia A (2006) Radiobiology for the radiologist, 6th edn. JB Lippincott, Philadelphia
3. Overgaard J, Hansen HS, Andersen AP, Hjelm-Hansen M, Jørgensen K, Sandberg E, Berthelsen A, Hammer R, Pedersen M (1989) Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: Report from the DAHANCA 2 study. Int J Radiat Oncol Biol Phys 16(4):1065-1068
4. Hoff CM, Grau C, Overgaard J (2012) Effect of smoking on oxygen delivery and outcome in patients treated with radiotherapy for head and neck squamous cell carcinoma-a prospective study. Radiother Oncol 103(1):38-44
5. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P (1996) Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56(19):4509-4515
6. Brizel DM, Dodge RK, Clough RW, Dewhirst MW (1999) Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome. Radiother Oncol 53(2):113-117
7. Bennett M, Feldmeier J, Smee R, Milross C (2007) Hyperbaric oxygenation for tumour sensitisation to radiotherapy: A systematic review of randomised controlled trials. Cancer Treat Rev 34(7):577-591
8. Marotta D, Karar J, Jenkins WT, Kumanova M, Jenkins KW, Tobias JW, Baldwin D, Hatzigeorgiou A, Alexiou P, Evans SM, Alarcon R, Maity A, Koch C, Koumenis C (2011) In vivo profiling of hypoxic gene expression in gliomas using the hypoxia marker EF5 and laser-capture microdissection. Cancer Res 71(3):779-789
9. Seigneuric R, Starmans MH, Fung G, Krishnapuram B, Nuyten DS, van Erk A, Magagnin MG, Rouschop KM, Krishnan S, Rao RB, Evelo CT, Begg AC, Wouters BG, Lambin P (2007) Impact of supervised gene signatures of early hypoxia on patient survival. Radiother Oncol 83(3):374-382
10. Bristow RG, Hill RP (2008) Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 8(3):180-192
11. Overgaard J, Hjelm-Hansen M, Johansen LV, Andersen AP (1988) Comparison of conventional and split-course radiotherapy as primary treatment in carcinoma of the larynx. Acta Oncol 27(2):147-152
12. Overgaard J, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, Bentzen J, Bastholt L, Hansen O, Johansen J, Andersen L, Evensen JF (2003) Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 362(9388):933-940
13. Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, Garden AS, Ridge JA, Cooper JS, Ang KK (2000) A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys 48(1):7-16
14. Withers HR, Maciejewski B, Taylor JM, Hliniak A (1988) Accelerated repopulation in head and neck cancer. Front Radiat Ther Oncol 22:105-110
15. Fyles A, Keane TJ, Barton M, Simm J (1992) The effect of treatment duration in the local control of cervix cancer. Radiother Oncol 4:273-279
16. Starmans MH, Krishnapuram B, Steck H, Horlings H, Nuyten DS, van de Vijver MJ, Seigneuric R, Buffa FM, Harris AL, Wouters BG, Lambin P (2008) Robust prognostic value of a knowledge-based proliferation signature across large patient microarray studies spanning different cancer types. Br J Cancer 99(11):1884-1890
17. West CM, Davidson SE, Roberts SA, Hunter RD (1997) The independence of intrinsic radiosensitivity as a prognostic factor for patient response to radiotherapy of carcinoma of the cervix. Br J Cancer 76(9):1184-1190
18. Björk-Eriksson T, West CM, Karlsson E, Slevin NJ, Davidson SE, James RD, Mercke C (1998) The in vitro radiosensitivity of human head and neck cancers. Br J Cancer 77(12):2371-2375
19. Björk-Eriksson T, West C, Karlsson E, Mercke C (2000) Tumor radiosensitivity (SF2) is a prognostic factor for local control in head and neck cancers. Int J Radiat Oncol Biol Phys 46(1):13-19
20. Olive PL (2011) Retention of cH2AX foci as an indication of lethal DNA damage. Radiother Oncol 101(1):18-23
21. Buyyounouski MK, Balter P, Lewis B, D'Ambrosio DJ, Dilling TJ, Miller RC, Schefter T, Tomé W, Harris EE, Price RA Jr, Konski AA, Wallner PE (2012) Stereotactic body radiotherapy for earlystage non-small-cell lung cancer: Report of the ASTRO emerging technology committee. Int J Radiat Oncol Biol Phys 78(1):3-10
22. Bral S, Gevaert T, Linthout N, Versmessen H, Collen C, Engels B, Verdries D, Everaert H, Christian N, De Ridder M, Storme G (2011) Prospective, risk-adapted strategy of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: Results of a phase II trial. Int J Radiat Oncol Biol Phys 80(5):1343-1349
23. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, Fowler J, Gore E, Choy H (2010) Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303(11):1070-1076
24. Gupta AK, McKenna WG, Weber CN, Feldman MD, Goldsmith JD, Mick R, Machtay M, Rosenthal DI, Bakanauskas VJ, Cerniglia GJ, Bernhard EJ, Weber RS, Muschel RJ (2002) Local recurrence in head and neck cancer: Relationship to radiation resistance and signal transduction. Clin Cancer Res 8(3):885-892
25. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK, Milas L (2002) Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62(24): 7350-7356
26. Vincent MD, Kuruvilla MS, Leighl NB, Kamel-Reid S (2012) Biomarkers that currently affect clinical practice: EGFR. ALK, MET, KRAS Curr Oncol 19(1):S33-S44
27. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(6):567-578
28. Curran D, Giralt J, Harari PM, Ang KK, Cohen RB, Kies MS, Jassem J, Baselga J, Rowinsky EK, Amellal N, Comte S, Bonner JA (2007) Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 25(16):2191-2197
29. Chinnaiyan P, Huang S, Vallabhaneni G, Armstrong E, Varambally S, Tomlins SA, Chinnaiyan AM, Harari PM (2005) Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 65(8):3328-3335